Kayla Marsh
A5058240388- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Ovarian cancer diagnosis and treatment
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Ocular Oncology and Treatments
- Immunotherapy and Immune Responses
- HIV Research and Treatment
- Immunodeficiency and Autoimmune Disorders
- Epigenetics and DNA Methylation
- Genomic variations and chromosomal abnormalities
- Advanced biosensing and bioanalysis techniques
- Lung Cancer Treatments and Mutations
- Protist diversity and phylogeny
- Esophageal Cancer Research and Treatment
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Histone Deacetylase Inhibitors Research
- Plant Gene Expression Analysis
- Antioxidant Activity and Oxidative Stress
- Single-cell and spatial transcriptomics
- Microbial infections and disease research
University of British Columbia
2025
Ontario Institute for Cancer Research
2018-2024
Institute of Cancer Research
2018-2022
St. Anthony’s Hospital
1972
People with Li-Fraumeni syndrome (LFS) harbor a germline pathogenic variant in the TP53 tumor suppressor gene, face near 100% lifetime risk of cancer, and routinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for range clinical applications, including early cancer detection. Here, we provide proof-of-principle multimodal liquid assay that integrates targeted gene panel, shallow whole-genome, cell-free methylated DNA immunoprecipitation sequencing...
Abstract Early kinetics of circulating tumor DNA (ctDNA) in plasma predict response to pembrolizumab but typically requires sequencing matched tissue or fixed gene panels. We analyzed genome-wide methylation and fragment-length profiles using cell-free methylated immunoprecipitation (cfMeDIP-seq) 204 samples from 87 patients before during treatment with a pan-cancer phase II investigator-initiated trial (INSPIRE). trained signature independent array data The Cancer Genome Atlas quantify...
To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms resistance PARP inhibitors (PARPi) in high-grade serous ovarian cancer (HGSOC).
Abstract Background In high grade serous ovarian cancer (HGSOC), there is a spectrum of sensitivity to first line platinum‐based chemotherapy. This study molecularly characterizes HGSOC patients from two distinct groups chemotherapy responders (good vs. poor). Methods Following primary debulking surgery and intravenous carboplatin/paclitaxel, women with stage III–IV were grouped by response. Patients in the good response (GR) poor (PR) respectively had progression‐free intervals (PFI) ≥12 ≤6...
Uveal melanomas are rare tumors arising from melanocytes that reside in the eye. Despite surgical or radiation treatment, approximately 50% of patients with uveal melanoma will progress to metastatic disease, most often liver. Cell-free DNA (cfDNA) sequencing is a promising technology due minimally invasive sample collection and ability infer multiple aspects tumor response. We analyzed 46 serial cfDNA samples 11 over 1-year period following enucleation brachytherapy (n = ∼4/patient) using...
The correlation between blood-based tumor mutation burden (bTMB) and tissue-based burden(tTMB) has not been broadly tested in a multicancer cohort. Here, we assess the bTMB with tTMB phase I trial patients treated immunotherapy. As an exploratory analysis, evaluated circulating DNA (ctDNA) dynamics responders.
Summary Despite advances in cancer therapeutics, early detection is often the best prognostic indicator for survival ( 1 ). People with Li-Fraumeni syndrome harbor a germline pathogenic variant tumor suppressor gene TP53 2 ) and face near 100% lifetime risk of developing wide spectrum of, multiple, cancers 3 mutation carriers routinely undergo intensive surveillance protocols which, although associated significantly improved survival, are burdensome to both patient health care system 4...
2550 Background: Bespoke mutation-based circulating tumor DNA (ctDNA) predicts response to P but relies on availability of tissue and presence mutations. Cell-free methylated immunoprecipitation high-throughput sequencing (cfMeDIP-seq) may overcome these limitations be applied more pts. Methods: Pts with mixed solid tumors divided into 5 cohorts received 200 mg Q3wks in the investigator-initiated INSPIRE trial (NCT02644369). cfMeDIP-seq was performed at baseline (B), pre cycle 3 (C3) later...
5561 Background: Patients with advanced high grade serous ovarian cancer (SOC) who undergo a suboptimal debulking primary surgery typically have adverse clinical outcomes. However, spectrum of sensitivity to first line platinum-based chemotherapy is observed but poorly understood. In this study, we perform molecular characterization two groups responders (extreme versus poor) carboplatin/taxol in suboptimally debulked SOC patients. Methods: Suboptimally patients disease (stage III-IV) were...
<p>Figure S9 showing fragment length metrics in cfMeDIP libraries</p>
<p>Figure S2 showing panel-based TP53 copy number alterations</p>
<p>Supplemental Table 1 – Sample Descriptions</p>
<p>Figure S2 showing panel-based TP53 copy number alterations</p>
<p>Figure S12 showing longitudinal integration scores</p>
<p>Supplemental Table 4 – LFS Methylation Signature</p>
<p>Figure S10 showing validation of methylation signatures</p>
<p>Supplemental Table 9 – Sequencing Coverages</p>
<p>Figure S11 showing comparison between uni-modal and multi-modal integration of assays</p>
<p>Figure S5 showing fragment size analysis for the detection of somatic variants</p>
<p>Figure S4 showing effects of germline copy number alterations on tumor fraction prediction</p>
<p>Figure S13 showing comparison of tumor and plasma copy number alterations</p>
<p>Figure S4 showing effects of germline copy number alterations on tumor fraction prediction</p>